YOMOGI® – Saccharomyces cerevisiae (boulardii) HANSEN CBS 5926 also known as CNCM I 745
Yomogi® is able to help maintain, restore and promote a healthy normal microflora.
Yomogi® – active substance a tropical strain of yeast, Saccharomyces cerevisiae (boulardii) HANSEN CBS 5926 / CNCM I 745
patient friendly blister packaging – heat stable – no refrigeration required – ideal for traveling
Available in two pack sizes: 20 and 50 capsule packs
Recommended Retail Price: 20 capsule packs $ 15.00
50 capsule packs $ 29.00
- Product Features
- Other ingredients
- Patient Handout - Patient Information Leaflet
At release – minimum 2.5 billion viable cells of Saccharomyces cerevisiae HANSEN CBS 5926 (synonym: Saccharomyces boulardii) in 250 mg lyophilisate.
Children: 2-6 years of age, same dosage but the hard capsule is to be opened and contents stirred into food or liquid
Travellers’ diarrhoea: 1 capsule 1-2 times daily starting 5 days before departure and continue for the duration of travel.
If diarrhoea persists for more than 6 hours in infants under 6 months, 12 hours in children under 3 years, 24 hours in children 3-6 years or 48 hours in adults and children over 6 years, seek medical advice.
Contains lactose. For diabetics, taking 1 hard Yomogi® capsule should be calculated as 0.01 carbohydrate exchange units.
The efficacy and safety of adding the probiotic Saccharomyces boulardii standard triple therapy for eradication of H.pylori: a randomized controlled trial. Zojaji H et al; Gastroenterol Hepatol Bed Bench 2013;6(Suppl.1):S99-S104.
Whilst travelling in Indochina during the early 1920’s, a Cholera outbreak had French microbiologist, Henri Boulard observe how the local population drank a tea that they had made from macerating tropical fruits (lychee and mangosteen) in order to prevent and treat diarrhoea.
Boulard continued his investigation and in 1923 was able to isolate the particular yeast strain responsible and named this Saccharomyces boulardii.
Saccharomyces boulardii is a non-pathogenic, non-systemic, eukaryotic microorganism that can grow under both aerobic and anaerobic conditions and at a high temperature of 37°C.
The strain Saccharomyces boulardii has been the subject of many pharmacological and clinical studies and is used today around the world as a probiotic in the treatment of diarrhoea.
Yomogi® as a probiotic drug contains 250 mg lyophilized yeast of Saccharomyces cerevisiae (boulardii) HANSEN CBS 5926 with minimum of 2.5 billion CFU at product release.
Lyophilization is a process of ‘freeze drying’ whereby ice is directly turned into vapour without first melting into a liquid state. This manufacturing process results in Yomogi® maintaining its integrity, quality and stability, so no cool storage of Yomogi® is necessary.
Once ingested Saccharomyces boulardii exerts its intraluminal effects but will not colonise the gastrointestinal tract. Rather, it is a transient yeast that provides benefits to the host as it moves. Approximately 4-6 days after cessation of Yomogi® administration, S boulardii yeast can no longer be detected in the stool.
Yomogi is able to bind pathogens, makes their bacterial toxins harmless and helps to excrete them from the gastrointestinal tract
Saccharomyces boulardii has shown to have many properties:
Within the lumen of the digestive tract Saccharomyces boulardii has antagonistic and antitoxic effects against pathogenic bacteria and yeasts.
S.boulardii is able to secrete a protein/microcin that inhibits the growth of these microorganisms.
S.boulardii has been shown to bind pathogenic bacteria such as Salmonella and specific fimbriae expressing Escherichia coli on their surface. In doing so S.boulardii reduces their adhesion to the intestinal epithelium and eliminates them from the intestine.
Bacterial toxins, such as those produced by Clostridium difficile are enzymatically neutralized by S.boulardii
S.boulardii displays beneficial effects against other pathogenic bacteria such as Salmonella and Yersnia
Effect on the intestinal mucosa and immune system
The antisecretory effect of S.boulardii helps normalise the water and electrolyte homeostasis. Administration of S.boulardii leads to an increase in the disaccharidase activity which improves the absorption of carbohydrates.
S.boulardii stimulates the production the production of secretory immunoglobulin A (sigA) in the gut associated lymphoid tissue and thereby helps strengthen the digestive tract defences against infections.
Acute diarrhoea is often caused by bacteria or viruses. Apart from the increased frequency of bowel movements and a more liquid stool consistency, fluid and electrolytes are lost to various degrees which can cause life-threatening dehydration. As causal therapy is often impossible, symptomatic treatment becomes important. This includes the normalisation of the water and electrolyte homeostasis. Clinical studies on both children and adults demonstrated the efficacy of the administration of S. boulardii for the treatment of acute diarrhoea.
Antibiotic-associated diarrhoea occurs in about 30% of patients who undergo antibiotic therapy. Patients of advanced age, with compromised immune status or prolonged hospital stays are at higher risk of developing these symptoms. For this indication, S. boulardii has protective and therapeutic effects on the intestinal mucosa. Several clinical studies have demonstrated the yeast reduces the frequency, duration and severity of an antibiotic-associated diarrhoea and helps prevent relapses.
Tourists are exposed to higher infectious risk in areas with low hygiene status. Common pathogens in traveller’s diarrhoea include enterotoxigenic E. coli and Salmonella. The main source of infection is food and water contamination. Therefore, the first and most effective prophylaxis is good hygiene, e.g. eating only peeled or cooked food and drinking boiled water. S. boulardii exerts prophylactic therapeutic effects on traveller’s diarrhoea as demonstrated in clinical studies.